专利检索 ap:("KOSMIN, Gerald, Emmanuel" OR "STATE OF ISRAEL, REPRESENTED BY PRIME MINISTER'S OFFICE, ISRAEL INSTITUTE FOR BIOLOGICAL RESEARCH") AND inv:"MARCIANO, Daniele" 第 1 页

1.

发明公开
AZA SPIRO COMPOUNDS ACTING ON THE CHOLINERGIC SYSTEM WITH MUSCARINIC AGONIST ACTIVITY 失效
标题翻译：与毒蕈碱AGONISTICHER活动ACTING AZA螺环化合物胆碱能系统

公开(公告)号：EP0711292A1

公开(公告)日：1996-05-15

申请号：EP94921036.0

申请日：1994-07-15

申请人： KOSMIN, Gerald, Emmanuel , STATE OF ISRAEL, REPRESENTED BY PRIME MINISTER'S OFFICE, ISRAEL INSTITUTE FOR BIOLOGICAL RESEARCH

发明人： FISHER, Abraham , KARTON, Yishal , MARCIANO, Daniele , BARAK, Dov , MESHULAM, Haim

IPC分类号： C07D487 , A61K31 , A61P25 , C07D453 , C07D471 , C07D491 , C07D497 , C07D498 , C07D513

CPC分类号： C07D471/10 , C07D491/10 , C07D497/10 , C07D513/10

摘要： The invention relates to spiro compounds having central and peripheral nervous system activity, for example muscarinic agonist activity, having formulae (I, II, III, IV, V, VI, VII, VIII and IX) and their pharmaceutically acceptable salts, quaternary compounds which are structurally derived from said compounds having a tertiary nitrogen atom, enantiomers and racemates, wherein ring A together with the spiro-carbon atom constitutes a bridged or unbridged ring containing one or two ring nitrogen atoms, and the value of each of the other symbols in the formulae is defined.

2.

发明授权
AZA SPIRO COMPOUNDS ACTING ON THE CHOLINERGIC SYSTEM WITH MUSCARINIC AGONIST ACTIVITY 失效
标题翻译：与毒蕈碱AGONISTICHER活动ACTING AZA螺环化合物胆碱能系统

公开(公告)号：EP0711292B1

公开(公告)日：2002-01-23

申请号：EP94921036.3

申请日：1994-07-15

申请人： KOSMIN, Gerald, Emmanuel , STATE OF ISRAEL, REPRESENTED BY PRIME MINISTER'S OFFICE, ISRAEL INSTITUTE FOR BIOLOGICAL RESEARCH

发明人： FISHER, Abraham , KARTON, Yishal , MARCIANO, Daniele , BARAK, Dov , MESHULAM, Haim

IPC分类号： C07D471/10 , A61K31/435 , C07D498/10 , C07D453/02 , C07D497/10 , C07D513/10

CPC分类号： C07D471/10 , C07D491/10 , C07D497/10 , C07D513/10

摘要： The invention relates to spiro compounds having central and peripheral nervous system activity, for example muscarinic agonist activity, having formulae (I, II, III, IV, V, VI, VII, VIII and IX) and their pharmaceutically acceptable salts, quaternary compounds which are structurally derived from said compounds having a tertiary nitrogen atom, enantiomers and racemates, wherein ring A together with the spiro-carbon atom constitutes a bridged or unbridged ring containing one or two ring nitrogen atoms, and the value of each of the other symbols in the formulae is defined.